SCHEMBL25322649

SCHEMBL25322649

C[C@H]1CC[C@H](c2ccc(CN(C)C)cc2)NC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 6/20 0.41
LTA4H P09960 2/20 0.38
ALDH1A1 P00352 1/20 0.37
TSHR P16473 1/20 0.37
TAAR1 Q96RJ0 2/20 0.37
HRH4 Q9H3N8 1/20 0.36
GRM2 Q14416 1/20 0.33
LSS P48449 1/20 0.33
TTK P33981 1/20 0.33
AURKB Q96GD4 1/20 0.33
INCENP Q9NQS7 1/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
PARP1 P09874 2/20 0.32
PARP2 Q9UGN5 1/20 0.32
PARP3 Q9Y6F1 1/20 0.32
CHEK1 O14757 1/20 0.31
MAP2K1 Q02750 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24364832 0.86 HRH3 (0.43) HRH3TAAR1
SCHEMBL24365618 0.86 HRH3 (0.43) HRH3TAAR1
SCHEMBL25323362 0.84 HRH3 (0.41) HRH3TAAR1
SCHEMBL30551760 0.84 HRH3 (0.41) HRH3TAAR1
SCHEMBL24364795 0.82 ESR2 (0.33) ALDH1A1CHEK1
SCHEMBL25320228 0.82 ALDH1A1 (0.37) ALDH1A1TSHRTAAR1NOS1PARP1
SCHEMBL24364796 0.79 KCNH2 (0.32)
SCHEMBL4155153 0.79 MKNK1 (0.44) HRH3LTA4HALDH1A1TSHRTAAR1
SCHEMBL24233794 0.78 MAPT (0.39) ALDH1A1
SCHEMBL25321512 0.78 MAPT (0.39) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 US disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN HRH3 1270/4885LTA4H 1775/4885ALDH1A1 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.